Restoration of endogenous glucose-responsive insulin production

Restoration of endogenous glucose-responsive insulin production refers to re-establishing the body’s natural mechanism—primarily via pancreatic β-cells—of secreting insulin in a regulated manner in response to rising blood glucose concentrations[1][6][7]. In healthy individuals, β-cells detect elevated glucose and secrete insulin to maintain normoglycemia; in diabetes (especially type 1), this function is impaired or lost. The therapeutic aim is to regenerate or replace β-cell function or simulate their glucose-sensing and insulin-release abilities, thereby achieving physiological glycemic control. This can involve β-cell regeneration, transplantation, or bioengineering approaches, but the phrase itself does not specify a molecular drug target[1][6][7]. In summary, "Restoration of endogenous glucose-responsive insulin production" is not itself a molecular target, but a clinical and physiological endpoint; it should not be treated as a canonical molecular target for drug development or pharmacological profiling.